IL-10 Induces IL-10 in Primary Human Monocyte-Derived Macrophages via the Transcription Factor Stat3

Karl J. Staples, Timothy Smallie, Lynn M. Williams, Andy Foey, Bernie Burke, Brian M. J. Foxwell and Loems Ziegler-Heitbrock

*J Immunol* 2007; 178:4779-4785; doi: 10.4049/jimmunol.178.8.4779

http://www.jimmunol.org/content/178/8/4779

**Why The JI?**

- **Rapid Reviews!** 30 days* from submission to initial decision
- **No Triage!** Every submission reviewed by practicing scientists
- **Speedy Publication!** 4 weeks from acceptance to publication

*average

**References**

This article cites 44 articles, 30 of which you can access for free at:
http://www.jimmunol.org/content/178/8/4779.full#ref-list-1

**Subscription**

Information about subscribing to *The Journal of Immunology* is online at:
http://jimmunol.org/subscription

**Permissions**

Submit copyright permission requests at:
http://www.aai.org/About/Publications/JI/copyright.html

**Email Alerts**

Receive free email-alerts when new articles cite this article. Sign up at:
http://jimmunol.org/alerts
IL-10 Induces IL-10 in Primary Human Monocyte-Derived Macrophages via the Transcription Factor Stat3

Karl J. Staples,* Timothy Smallie, Lynn M. Williams, Andy Foey,2† Bernie Burke,* Brian M. J. Foxwell,† and Loems Ziegler-Heitbrock3*‡

IL-10 is an important immunosuppressive cytokine that can down-regulate expression of other cytokines and has been shown to down-regulate itself. We show, in this study, that treatment of human monocyte-derived macrophages with IL-10 induces IL-10 mRNA in a dose- and time-dependent manner with an optimum induction at 100 ng/ml and at 6 h, whereas IL-10-induced IL-10 protein can be detected at 18 h. In the same cells, IL-10 can partially suppress IL-10 mRNA induced by LPS, but only down to the level of IL-10-induced IL-10. An adenoviral luciferase reporter construct driven by the −195 IL-10 promoter, which contains a Stat motif, was readily induced by both IL-10 and LPS. Mutation of this Stat motif ablated IL-10 activation of this promoter, but not the LPS activation. Finally, we show that overexpression of a dominant-negative Stat3 protein will prevent IL-10 induction, but not LPS induction, of IL-10 mRNA. These data show that IL-10 induces IL-10 in monocyte-derived macrophages in an autocrine manner via activation of the transcription factor Stat3.

Interleukin 10 is an immunosuppressive cytokine produced by T cells, B cells, dendritic cells, and monocytes/macrophages (1–3). The immunosuppressive activity of IL-10 is highlighted by the findings that IL-10 knockout mice show increased autoimmune disease and increased resistance to infection (4, 5). As has been shown by the group of de Waal Malefyt et al. (6), IL-10 can suppress the immune response by decreasing cell surface expression of MHC class II and by down-regulating the expression of other cytokines. These early studies also noted that IL-10 could down-regulate expression of IL-10 induced by LPS.

IL-10 acts by binding to the IL-10R1/IL-10R2 receptor complex that recruits Jak1 and Tyk2, and these then phosphorylate and activate the transcription factor Stat3 (7, 8). Although IL-10 activates Stat3, we and others have provided evidence that IL-10 itself may be controlled by Stat3 binding to a cognate motif in the IL-10 promoter (9–11). These studies in human cells were supported by the group of de Waal Malefyt et al. (6), IL-10 can suppress the immune response by decreasing cell surface expression of MHC class II and by down-regulating the expression of other cytokines. These early studies also noted that IL-10 could down-regulate expression of IL-10 induced by LPS.

IL-10 acts by binding to the IL-10R1/IL-10R2 receptor complex that recruits Jak1 and Tyk2, and these then phosphorylate and activate the transcription factor Stat3 (7, 8). Although IL-10 activates Stat3, we and others have provided evidence that IL-10 itself may be controlled by Stat3 binding to a cognate motif in the IL-10 promoter (9–11). These studies in human cells were supported by the group of de Waal Malefyt et al. (6), IL-10 can suppress the immune response by decreasing cell surface expression of MHC class II and by down-regulating the expression of other cytokines. These early studies also noted that IL-10 could down-regulate expression of IL-10 induced by LPS.

Materials and Methods

Materials

Salmonella abortus equi (S.ae) LPS was purchased from Axxora Life Sciences. Recombinant human IL-10 (rhIL-10) was obtained from R&D Systems and murine IL-10 was obtained from PeproTech. Polymyxin B (PMB) was purchased from Sigma-Aldrich.

Generation of MDM

PBMC were isolated from heparinized (10 U/ml) blood from healthy donors by centrifugation on Ficoll-Paque (Amersham Biosciences) according to the manufacturer’s instructions. CD14+ cells were positively selected from PBMC using MACS CD14 microbeads (Miltenyi Biotec) according to the manufacturer’s instructions. Cells were resuspended at a density of 1 × 106 cells/ml in RPMI 1640 medium as previously described (10). Cells were cultured in 6-well Costar ultra-low attachment microplates (Costar) 3 days before any analyses or manipulation.

Plasmids

The four −195-bp IL-10-promoter fragments and the p4xM67-tk-luci (Stat reporter) were generated as previously described (10, 13). These promoter constructs were further subcloned into the pAdTrack vector (Qiagen) to generate pAdT.IL10−195.statm-luc, pAdT.IL10−195.stat-luc, pAdT.IL10−195.statm-luc, and pAdT.4xM67-tk-luc.

The full-length murine human (m/h) IL-10R1 chimeric construct was generated through the introduction of an SspI site in the membrane-proximal sequence of the 5′ section of the mIL-10R1 and the 3′ section of the hIL-10R1 using primers 5′Murine and 3′Human SspI. The PCR fragments were cloned into an intermediate blunt-end cloning vector using the pCR Blunt II vector and TOPO cloning kit (Invitrogen Life Technology). The 5′ primer contained a Msel, and all 3′ primers contained a HindIII site to allow directional subcloning of the PCR fragment. All standard PCRs were conducted as 4 min at 92°C, then 35 cycles at 30 s 92°C, 30 s at 60°C, 2 min at 72°C per cycle, and then 10 min at 72°C. Primers used were 5′Murine 5′-GCT ACG ATG TTG TCG GTG CTT CTC CCA-3′, 3′ Murine SspI 5′-GCT AGC ATG TTG TCG GTG CTT CTC CCA-3′, 3′ Human SspI 5′-GCT AGC GTG CAC AAG CCT GTG CTC CCA-3′; 5′ Human SspI 5′-CAG CAG GCA ATA TTT CGT GCC GTT GTG-3′.

Abbreviations used in this paper: MDM, monocyte-derived macrophage; rhIL-10, recombinant human IL-10; AdV, adenovirus; MOI, multiplicity of infection; PMB, polymyxin B; Sae, Salmonella abortus equi; WT, wild type; IRF, IFN regulatory factor; dn, dominant negative; β2m, β2-microglobulin; m, murine; h, human.

Copyright © 2007 by The American Association of Immunologists, Inc. 0022-1767/07/$2.00

*Department of Infection, Immunity and Inflammation, University of Leicester, Leicester, U.K.; †Kennedy Institute of Rheumatology, Imperial College School of Medicine, London, U.K.; and Clinical Cooperation Group Inflammatory Lung Diseases, Asklepios Fachkliniken and GSF National Research Center, Robert Koch Alter 29, Gauting, Germany.

Received for publication August 30, 2006. Accepted for publication January 23, 2007.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 This work was supported by Grant 91-C19230 from the Biotechnology and Biological Sciences Research Council.

2 Current address: School of Biological Sciences, University of Plymouth, Drake Circus, Plymouth, U.K.

3 Address correspondence and reprint requests to Dr. Loems Ziegler-Heitbrock, Department of Infection, Immunity and Inflammation, University of Leicester, Medical Sciences Building, University Road, Leicester, U.K. E-mail address: lzh1@leicester.ac.uk

www.jimmunol.org
and 3′Human FLAG 5′-AAG CTT TCA CTG GTC TTC GTA GTC ACT TGA CTA GA-3′. The full-length m/h IL-10RI chimeric construct was excised from TOPO using NheI/HindII and cloned into pAd5, which had also been opened with XbaI/HindIII.

Adenoviral vectors and their propagation

The AdEasy Vector Kit (Qbiogene) was used to generate recombinant replication-deficient viruses according to the manufacturer’s instructions and as previously described (14, 15). The Adeno-X Rapid Titer Kit (BD Biosciences) was used to determine viral titer. A recombinant, replication-deficient adenoviral vector encoding the dominant-negative human STAT-3 Tyr705 deficient adenoviral vector encoding the dominant-negative human STAT-3 Tyr705 (S3 DN) (16) was provided by Y. Fasjio (University of Osaka, Osaka, Japan). An identical construct lacking the insert (Ad0) was provided by A. Byrnes and M. Wood (University of Oxford, Oxford, U.K.).

Adenoviral infection of MDM

MDM were infected with luciferase reporter viruses and the Stat3DN adenovirus (AdV) for 2 h in serum-free medium in 24-well Costar ultra-low attachment plates. After infection, cells were harvested and resuspended in 90 l of medium containing 5% FCS, and 10 μl of human IL-10 catch reagent (Miltenyi Biotec) was then added. The full-length m/h IL-10RI chimeric Adv at 1 MOI overnight in medium containing 5% FCS in 24-well Costar ultra-low attachment plates.

Luciferase assay

Infected cells were replated at 3.75 × 10^6 cells in 1 ml of medium onto a 24-well Costar ultra-low attachment plate before being subjected to stimulation for 6 h. Cells were then harvested and resuspended in 1 × reporter lysis buffer (Promega). Luciferase activity in cell lysates was determined using a Sirius model luminometer (Berthold Technologies) and the Luciferase Assay System from Promega. Protein concentrations were determined using Bio-Rad DC Protein Assay reagents (Bio-Rad).

RNA and protein isolation

RNA was isolated from cells using TRI Reagent (Sigma-Aldrich) according to the manufacturer’s instructions. Protein was isolated using either TRI Reagent or with cells being lysed with buffer A (10 mM HEPES (pH 7.9), 10 mM KCl, and 1.5 mM MgCl2) supplemented with 10 μg/ml aprotinin, 1 mM PMSF, 40 μg/ml leupeptin-propionyl, 20 μg/ml pepstatin A, and 2 mM DTT, as indicated.

Relative quantification of IL-10 mRNA expression using real-time RT-PCR

Reverse transcription of isolated RNA was conducted as previously described (17). Reverse transcription products (3 μl) were amplified in a 20-μl reaction mix containing 1 × SYBR Green Taq ReadyMix Capillary Formulation (Sigma-Aldrich), 1.5 mM MgCl2, and 0.375 μM of each primer. Primers for IL-10 were forward 5′-GCC TAA CAT GCT TCG AGA TC-3′ and reverse 5′-GTA TGT CTG GCT GTT GGT TC-3′. Primers for β2-microglobulin (β2m) were forward 5′-GCC TAT CCA GCG TAC TCC AAA G-3′ and reverse 5′-CAA TTT CCA TGT CGG ATG GAT G-3′. Amplifications were conducted on a Roche LightCycler using the following cycling parameters: preincubation at 95°C for 10 min, then 96°C for 10 s, 60°C for 10 s, and then 72°C for 25 s. All reactions were finished with a melting curve run to establish the specificity of the PCR. Data are expressed as a ratio to β2m.

Western blot analysis

Ten micrograms of protein was resolved on a 4–12% Novex Tris-glycine gel (Invitrogen Life Technologies) and transferred to Hybond-N membranes (Amersham Biosciences) using a Novex X-Cell II Mini Cell. Blots were reacted with a pStat3 (Tyr705) Ab (SC 7993R; Santa Cruz Biotechnology) or polyclonal Stat3 Ab (SC 482; Santa Cruz Biotechnology) as indicated, followed by peroxidase-conjugated anti-rabbit IgG (A0545; Sigma-Aldrich). Blots were developed using the ECL kit (Amersham Biosciences) and were visualized on Kodak BioMax X-Omat AR film (Sigma-Aldrich).

Secretion assay for human IL-10 protein

After infection, cells were harvested and resuspended in 90 μl of medium containing 5% FCS, and 10 μl of human IL-10 catch reagent (Miltenyi Biotec) was then added. After a 5-min incubation on ice, 900 μl of serum-containing medium was added and the cells were stimulated as indicated. Cells were incubated at 37°C for ~18 h with rotation. Cells were then treated as per the manufacturer’s instructions. They were then stained with anti-IL-10 and initially gated on the GFP⁺ population. Positive signals in gate M1 were determined and expressed as specific mean fluorescence
in the presence of the Miltenyi Biotec catch reagent. Cells were then incubated with the allophycocyanin-labeled IL-10 detection reagent and were analyzed overnight before being resuspended in fresh serum-supplemented medium. After resuspension, cultures were treated with mIL-10 (100 ng/ml) for 6 h. PBMC were cultured for 2 days before treatment with empty AdV or the m/h IL-10R chimera AdV at a titer of 1 MOI. Cells were cultured and RNA was extracted and reverse transcribed. IL-10 and IL-10 mRNA was determined as described above. Data from at least three independent experiments are expressed as means ± SD. C and D, Induction of IL-10 protein. PBMC were cultured for 2 days before treatment with empty AdV or the m/h IL-10R chimera AdV. Average ± SD of three independent experiments, further analyzed using a paired t test. *, p < 0.05.

Statistics
Analyses were performed using a paired t test. Results were considered significant if p ≤ 0.05 (***, p ≤ 0.001; ***, p ≤ 0.01; and *, p ≤ 0.05).

Results
MDM: characteristics and infection by recombinant AdV
For generation of MDM, we isolated PBMCs and cultured these cells for 3 days in low-attachment plates. The MDM derived in this fashion expressed statistically significant greater amounts of CD14 (2-fold), CD16 (5-fold), and CD68 (6-fold) compared with freshly isolated PBMC as measured by FACS (Fig. 1A). The increase in expression in the latter two markers is consistent with maturation to macrophages. Such cells could be readily infected with AdV, which were added on day 3. This led to a robust infection rate with >80% of all CD14+ MDM being GFP positive at 100 MOI, as measured by FACS. Positivity of macrophages, but not lymphocytes, is evident in fluorescence microscopy analysis (Fig. 1B).

IL-10 induces IL-10 mRNA in human MDM
Because IL-10 acts via activation of Stat3, and because we have shown that Stat3 is a crucial transcription factor controlling the IL-10 promoter (9, 10), we asked whether IL-10 might be able to induce its own gene. Addition of IL-10 protein (100 ng/ml) to human MDM, in fact, led to an 8-fold induction of IL-10 mRNA (Fig. 2A). At 1 ng IL-10/ml, there was still a 4-fold induction, but lower concentrations of the cytokine had no effect. To demonstrate that this was a genuine effect of IL-10 and not of contaminant LPS, we heat-treated IL-10 at 10 ng/ml, and this ablated all activity. Conversely, addition of 1 µg/ml PMB to IL-10 (10 ng/ml) had no effect on IL-10 mRNA production, whereas the same amount of PMB was able to block the induction caused by exogenous LPS from S.ae (Fig. 2A). Time-course analysis revealed a rapid induction of IL-10 mRNA by IL-10 in that a significant expression was already evident at 1 h with a plateau from 4 to 8 h. Again, PMB was unable to neutralize the action of IL-10 at 6 h (Fig. 2B).

IL-10 induces IL-10 protein in human MDM
The induction of IL-10 mRNA led us to investigate whether protein was also being induced. Cells cultured for 24 h with LPS (100 pg/ml) produced, on average, 120.4 pg/ml IL-10 protein (±SD, 80.2, n = 3) as measured by IL-10 ELISA. However, it was not possible to use the standard ELISA approach for analysis of IL-10-induced IL-10 protein, because of the problem of differentiating the exogenous human IL-10 used for stimulation and the endogenous human IL-10 produced in the culture. We therefore tried to detect IL-10-induced IL-10 protein using metabolic labeling, but could not induce a signal, possibly due to the low sensitivity of the system (data not shown). We therefore used a chimeric IL-10R construct consisting of a murine extracellular portion and a human
transmembrane and intracellular domain. This construct was delivered to MDM using adenoviral vectors and, unlike the endogenous human receptor, it responds to murine IL-10 by signaling via the human intracellular domain (18). Infected cells were stimulated overnight with recombinant murine IL-10, and the human IL-10 protein released was determined by cell surface staining using the secretion assay. As shown in Fig. 2C, treatment of cells expressing the m/h IL-10R with murine IL-10 induced detectable human IL-10 protein, unlike cells infected with an empty control virus (Fig. 2D). The levels of IL-10 were low but significant and show that IL-10 can induce its own protein in an autocrine fashion.

**IL-10, but not LPS, induces IL-10 promoter activity via Stat3**

In earlier studies in a B cell line, we demonstrated a crucial role for the -120 Stat motif of the human IL-10 promoter in controlling expression of the gene (9, 10). To study the role of this promoter

**FIGURE 3.** Stat3 is essential for IL-10 induction of the IL-10 promoter, but dispensable for LPS induction in MDM. PBMC were cultured for 3 days before treatment with or without AdV, as indicated, at a MOI of 100 for 2 h in serum-free medium. After addition of serum, cells were cultured overnight before being resuspended in fresh serum-supplemented medium. After resuspension, cultures were not treated (NT, □) or treated (■) with rhIL-10 (10 ng/ml) or S.ae LPS (100 ng/ml), as indicated, for 6 h. After incubation, cells were harvested and luciferase (Luc) activity and protein concentration were measured. Data were normalized to protein concentration and are expressed as means ± SD of four independent experiments.

**FIGURE 4.** Induction of IL-10 by LPS and IL-10 is specific to MDM. A, PBMC separated by MACS into CD14⁺ cells (■) or CD14-depleted cells (DEP, □) were cultured for 3 days before treatment with or without IL-10 (10 ng/ml) and/or S.ae LPS (100 pg/ml). Cells were harvested after 6 h, and RNA was extracted and reverse transcribed. IL-10 and β₂m steady-state mRNA levels were determined using real-time PCR. Data were normalized to β₂m and are expressed as fold induction over untreated sample. Data from four independent experiments are expressed as means ± SD and further analyzed using a paired t test. *, p < 0.05 when compared with the CD14, S.ae-treated sample. B, CD14⁺ cells were cultured for 3 days before treatment with IL-10 (10 ng/ml). Cells were harvested after 1 h and cells were lysed with buffer A. Protein (10 μg) from each experiment were run on SDS-PAGE and immunoblotted with anti-phospho-Stat3 (top), then the membrane was stripped and reprobed with anti-Stat3 (bottom). Blots representative of three independent experiments are shown. C, CD14⁺ cells were cultured for 3 days before treatment with IL-10 AdV at a MOI of 100 for 2 h in serum-free medium. After addition of serum, cells were cultured overnight before analyzing on a Zeiss Axiovert 135 fluorescent microscope using phase contrast (top) or fluorescent light with a FITC filter (bottom).
site in primary MDM, we have cloned wild-type (WT) and mutant IL-10 promoter fragments into an adenoviral luciferase reporter virus. Infection of MDM with WT virus showed an average 4.5-fold induction of the promoter by human IL-10 and 2.6-fold by LPS (Fig. 3). Mutation of the Stat site led to an ablation of the induction by IL-10, whereas mutation of the IFN regulatory factor (IRF) motif had no effect. Also, mutation of both the Stat site and the IRF site ablated activity consistent with the ablation seen with mutation of the Stat site alone (Fig. 3). In contrast, none of the mutations ablated activity of the LPS-induced promoter; indeed, mutations of the promoter seemed to enhance the LPS-induced luciferase activity. Furthermore, when we infected the MDM with an adenoviral reporter construct containing a tetrameric Stat motif (4xM67), we observed an almost 6-fold induction by IL-10, but almost no induction (average 1.3-fold) by LPS (Fig. 3). These data are in line with the concept of tissue-specific and signal-specific expression of the IL-10 gene in that Stat3 appears to be crucial for LPS-induced expression in a B cell line and not in primary macrophages, whereas upon stimulation with IL-10 in the same macrophages, Stat3 is used to control expression of the IL-10 gene.

IL-10 suppression of LPS-induced IL-10

The classical study on the biological activity of IL-10 reported that IL-10 can suppress its own expression (6). These studies were done with LPS stimulation with and without the addition of IL-10. We therefore analyzed the effect of IL-10 on LPS-induced IL-10 production in human MDM. As shown in Fig. 4A, addition of IL-10 to LPS did suppress the production of IL-10 mRNA by factor 2, confirming the earlier findings by de Waal Malefyt et al. (6). However, in the same experiments, we could confirm that IL-10 alone will induce IL-10 mRNA in these cells. Taken together, IL-10 will induce IL-10 in human MDM, but at the same time, it can reduce the LPS-induced activation. This suppression will not go below the level of the LPS-induced IL-10 mRNA. In addition, this production of IL-10 mRNA by rhIL-10 appears to be restricted to CD14+ MDM, as CD14-depleted cell cultures (i.e., lymphocytes) were essentially negative for IL-10-induced IL-10 mRNA (Fig. 4A).

IL-10 induces IL-10 via Stat3

Since many of the previous experiments were conducted in 3-day PBMC cultures, to further study the possible role of Stat3 in IL-10-induced IL-10, we set out to confirm that IL-10 can activate the transcription factor Stat3 in CD14+ MDM. As shown by Western blotting, tyrosine phosphorylation was clearly induced by IL-10 within 1 h in these cells (Fig. 4B). We could also show that CD14+ MDM were still susceptible to infection by AdV, with a similar rate of infection (>80% at 100 MOI, Fig. 4C).

To confirm the importance of Stat3 in IL-10-induced expression of IL-10 in human MDM, we infected CD14+ cells that had been cultured for 3 days with an AdV encoding a dominant-negative (dn) Stat3. When such cells were stimulated with rhIL-10, the induction of the endogenous IL-10 gene was completely blocked. In contrast, uninfected cells and cells infected with empty virus showed a clear-cut induction of IL-10 mRNA (Fig. 5A). Furthermore, overexpression of the dn Stat3 had no effect on LPS-induced IL-10 mRNA expression (Fig. 5B). This observation suggests that the down-regulation seen for IL-10-induced IL-10 cannot be attributed solely to a global down-regulation of mRNA expression caused by the dn protein. Collectively, these data show that IL-10 induces IL-10 by activating the transcription factor Stat3, but that LPS acts via a different signaling mechanism in primary human MDM.

Discussion

IL-10 was originally described as a cytokine synthesis inhibitory factor produced by murine Th2 cells (1). Along this line of IL-10 being a Th2 cytokine, it was also found to have some stimulatory activity for B cells (19). In humans, IL-10 was shown to be produced by both Th1 and Th2 cells (20), and IL-10 was found to suppress IgE production by B cells (21). Based on its ability to suppress cell-mediated and Ab-mediated responses, IL-10 is now considered to be a major immunosuppressive cytokine with potential as a therapy for various inflammatory diseases. We show in this study that IL-10 induces IL-10 in human primary MDM. This is in line with two studies that found an increase of IL-10 mRNA in leukocytes as part of an array approach (22, 23). Also, treatment of psoriasis patients with IL-10 led to expression of IL-10 mRNA in the skin (24). We show in this study in human macrophages that this induction is dose and time dependent, and that it leads to expression of both IL-10 mRNA and protein, and we analyzed the molecular mechanism involved. Although we have not systematically analyzed the effect of LPS-induced IL-10 in cells transduced with the adenoviral chimeric IL-10R, our preliminary data indicate that the level of IL-10 released is similar for LPS-stimulated and IL-10-stimulated macrophages under these conditions.

At first glance, these data could be considered to conflict with the original report by de Waal Malefyt et al. (6), who showed suppression of LPS-induced IL-10 by IL-10. We can, however,
confirm these findings and show a 2-fold suppression of LPS-induced IL-10 mRNA by IL-10 (Fig. 4A). Of note is the observation that IL-10 suppression of LPS-induced IL-10 reduces the level of IL-10 mRNA to the level of IL-10-induced IL-10 mRNA, but not any lower (i.e., the inductive effect of IL-10 on IL-10 is not overcome when IL-10 blocks LPS-induced IL-10). In experiments not shown, we have confirmed this finding with a higher dose of IL-10 (100 ng/ml) both for induction of IL-10 and suppression of LPS-induced IL-10.

Various transcription factors have been implicated in the regulation of the IL-10 gene. Expression of IL-10 directed by the murine promoter was shown to depend on Sp1 (25, 26). For the human IL-10 promoter, Sp1 was shown to be essential for expression in a monoblastic cell line (27), but in other studies, the same promoter element was shown to have a repressive function (28). A contribution of cAMP-responsive elements to catecholamine-driven transactivation has also been demonstrated (29), and, recently, it was shown that catecholamine action depends to a large extent on c/EBP-α (30). Finally, c-Maf was shown to transactivate the human promoter via a site at −196 bp (31). We have identified a Stat site at −120 bp in the human promoter and have provided evidence for the role of Stat3 in transactivation of the human promoter in B cells in response to both LPS and IFN-α (9, 10).

When it comes to IL-10 stimulation of cells, Stat3 is the main transcription factor invoked. IL-10 acts via the IL-10R, which consists of two chains, and ligand binding to the receptor will lead to phosphorylation of Jak1 and Tyk2 and then Stat3 (7, 8). We can confirm that IL-10 stimulation will lead to the phosphorylation of Stat3 in human MDM and that it will transactivate a tetrameric Stat reporter construct. Furthermore, we can demonstrate a role for Stat3 in IL-10-induced IL-10 production, based on the findings that IL-10 is inactive on a promoter with a mutated Stat site, and that overexpressing dn Stat3 blocks the induction of IL-10 mRNA expression.

Our data are in line with studies by Cheng et al. (12), who demonstrated a lack of IL-10 production in Stat3−/− mice, but they are at variance with the report of Takeda et al. (32), who showed increased IL-10 in such Stat3−/− animals. The discrepancy may be explained by the different approaches taken. In these knockout mice, Cheng et al. (12) have studied IL-10 production in LPS-stimulated peritoneal macrophages ex vivo. In contrast, Takeda et al. (32) have looked at serum IL-10 in animals injected with LPS. The latter approach may invoke additional, indirect mechanisms, which are independent of Stat3. For instance, one might speculate that increased induction of TNF in vivo in the Stat3−/− mice may induce IL-10 by a Stat3-independent mechanism. Still, in the system of human MDM as used in this study, LPS induction of IL-10 is not mediated by Stat3, because mutation of the Stat site does not prevent IL-10 promoter activity. In addition, LPS cannot stimulate activity of a tetrameric Stat reporter construct and overexpression of a dn Stat3 had no effect on LPS-induced IL-10 mRNA expression. Previously, we have shown that LPS induction of IL-10 depends on Stat3 in a B cell line (9), whereas in the present study, we show no requirement for Stat proteins for IL-10 production in primary macrophages upon LPS stimulation. This discrepancy likely reflects tissue-specific gene expression, but analysis in different types of B cells and macrophages is required to address this issue.

The role of Stat3 in IL-10 gene expression was, however, confirmed in several additional studies (33, 34). More recently, it was shown that SOCS3 deficiency in murine T cells led to increased Stat3 activity and IL-10 expression (35), and that constitutive IL-10 expression in T cell lines can be blocked by depletion of Stat3 by RNA interference (36).

Huang et al. (11) demonstrated that induction of IL-10 by LPS required Stat3 to be both tyrosine and serine phosphorylated. Tyrosine phosphorylation is a prerequisite for translocation of Stat1 into the nucleus (37), but for Stat3, nuclear transport can occur for unphosphorylated protein (38). Still, tyrosine phosphorylation is required for DNA binding and transactivation and, as shown in this study, IL-10 efficiently induces this phosphorylation in MDM (Fig. 4B).

Although it appears that Stat3 mediates the induction of IL-10 by IL-10, the mechanisms involved in IL-10-mediated down-regulation of LPS-induced IL-10 production remain unclear. The mechanism may be similar to the action of IL-4, which was shown to down-regulate IL-10 expression in murine dendritic cells in a process involving Stat6 (39). Additionally, Stat1 has been shown to be induced by IL-10 (40), and Stat1 was shown to mediate down-regulation of the IL-10 promoter (10). However, because we see a robust induction of the luciferase from the −195 promoter by LPS, the relevant element(s) for IL-10 inducibility have to be within this 5′ fragment. For the human gene, transactivation by catecholamines appears to require the action of C/EBP, and the most important motif TTGCAAAAA is located 44 bp downstream of the TATA box (30). Furthermore, there is evidence for a role of c-Maf in IL-10 gene expression, which is located directly next to the TATA sequence between −196 and −184 bp (31).

LPS has been shown to induce IFN-β followed by activation of Stat1 (41), and we have shown previously that Stat1 may act as a negative regulator of IL-10 expression (10). Hence, one might speculate that the slight increase in IL-10 promoter activity with the mutation of the Stat site might be due to the lack of IFN-β-induced Stat1 action. In experiments not shown, we found, however, no effect of exogenous IFN-β or anti-IFN-β Ab on promoter activity. Thus, although IFN-β may well be important in regulation of IL-10 (42, 43), it appears not to operate in the primary MDM used in this study.

We have provided evidence for a role of Stat3 in IL-10-induced IL-10 in primary human macrophages (i.e., macrophages derived from blood monocytes in vitro). It remains unclear at this point whether the same mechanisms will operate in other cells like B and T cells. For instance, Stat3 might play a role in T cells where IL-10 was shown to be a positive autocrine factor in the development of IL-10-producing regulatory T cells (44).

Taken together, we show in this study that IL-10 can induce expression of IL-10 in an autocrine fashion, which involves mobilization of the transcription factor Stat3. This positive autocrine feedback will allow IL-10 to enhance its immunosuppressive action.

Acknowledgments
We thank Dr. James Darnell (Rockefeller University, New York, NY) for provision of the p4xM67-tk-luc reporter plasmid, Dr. Brent Kiernan for experimental advice.

Disclosures
The authors have no financial conflict of interest.

References


